Given that the evidence and strength of recommendations for the use of SGLT-2 inhibitors or GLP-1 agonists in patients with type II diabetes and clinical ASCVD has only increased in recent years, it is possible that clinicians may experience clinical inertia when prescribing these medications for cardiovascular risk reduction. This evidence concerns the gene GCG and atherosclerosis.